Abbott/$ABT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Abbott

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Ticker

$ABT
Sector

Primary listing

NYSE

Employees

114,000

Abbott Metrics

BasicAdvanced
$233B
16.78
$7.97
0.70
$2.32
1.76%

What the Analysts think about Abbott

Analyst ratings (Buy, Hold, Sell) for Abbott stock.

Bulls say / Bears say

Abbott's medical device sales jumped 21.4% year-on-year to $1.9 billion in Q2 2025, driving total revenue to $11.14 billion and topping analyst projections, led by high demand for its continuous glucose monitors. (Reuters)
In Q1 2025, Abbott delivered adjusted EPS of $1.09, outperforming forecasts by $0.02, and confirmed its full-year profit guidance at $5.05–$5.25 per share, supported by strong demand in medical devices. (Reuters)
Abbott will invest $500 million to expand manufacturing and research operations in Illinois and Texas, aimed at reducing supply chain risk from tariffs and strengthening its long-term operational stability. (Reuters)
Abbott's Q1 2025 revenue was $10.36 billion, missing estimates by $40 million, mainly due to weakness in its diagnostics division. (Reuters)
Although Abbott beat Q2 earnings expectations, its shares fell more than 4% after the company released a Q3 profit outlook of $1.28–$1.32 per share, below the $1.34 average forecast, signaling possible deceleration. (Reuters)
Ongoing global tariff uncertainty focused on China is pressuring costs. With roughly 60% of sales coming from outside the U.S., Abbott also faces risks to margins and from currency movements. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.

Abbott Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Abbott Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ABT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

FAQs